Chang Carmen 4

What Happened

• Carmen Chang, reported as a 10% owner of Korro Bio, made purchases on March 10, 2026 totaling 450,045 securities for $4,999,757. The transactions were purchases: 207,100 shares of common stock at $11.11 each ($2,300,881) and 242,945 pre-funded warrants (derivative) at $11.11 each ($2,698,876). These were acquisitions from the issuer pursuant to a subscription arrangement and represent insider buying (a purchase, which some investors view as a bullish signal).

Key Details

• Transaction dates & prices: March 10, 2026 — 207,100 common shares at $11.11; 242,945 pre-funded warrants at $11.11.
• Total consideration: $2,300,881 (common stock) + $2,698,876 (pre-funded warrants) = $4,999,757.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1: Shares/warrants were acquired from the issuer under a Subscription Agreement dated March 9, 2026.
  • F3: The purchased pre-funded warrants are exercisable into common stock, subject to a standard ownership cap (generally a 9.99% cap unless the holder gives notice to change it), meaning exercise could be limited to avoid exceeding that threshold.
• Filing timeliness: Reported with a Form 4 filed March 12, 2026 for a March 10 transaction — appears to be timely (within standard Form 4 reporting window).

Context

• These are purchases (not sales). Purchases by insiders can be of interest to retail investors as a potential sign of confidence, but they do not prove future stock performance.
• The second line is a derivative purchase (pre-funded warrants). Those warrants must be exercised to become common shares; exercise may be restricted by an ownership limit described above.
• As a 10% owner, Chang’s transactions may reflect institutional/large-holder activity rather than routine executive payroll-related trades; interpret accordingly and consider collateral company information before making investment decisions.